ROLE OF MEDICATIONS WITH NEGATIVE CHRONOTROPIC EFFECT IN THE TREATMENT OF PATIENTS WITH CORONARY HEART DISEASE AND HEART FAILURE
https://doi.org/10.15829/1728-8800-2013-5-81-86
Abstract
The study aim was to assess the importance of adequate administration of medications with negative chronotropic effect in the improvement of clinical course and prognosis among patients with coronary heart disease (CHD) and heart failure. The possibility and appropriateness of combination therapy with β-adrenoblockers (β-AB) and an If channel blocker ivabradine is justified. The authors analyse current real-world trends in the administration and dose titration of these medications among ambulatory Russian patients. Russian doctors need to be more active in the treatment of patients with CHD and heart failure and better understand the need for and benefits of dose titration of medications with negative chronotropic effect, as well as the importance of combination therapy for the improvement of clinical course, prognosis, and quality of life.
About the Authors
M. G. Glezer
I.M. Sechenov First Moscow State Medical University, Moscow
Russian Federation
Russian Federation
E. I. Astashkin
I.M. Sechenov First Moscow State Medical University, Moscow
Russian Federation
Russian Federation
I. N. Sokolova
I.M. Sechenov First Moscow State Medical University, Moscow
Russian Federation
Russian Federation
References
1. National guidelines for the diagnosis and treatment of stable angina. Cardiovascular Therapy and Prevention 2008; 7 (6), Annex 4. Russian (Национальные рекомендации по диагностике и лечению стабильной стенокардии. Кардиоваскулярная терапия и профилактика 2008; 7 (6), Приложение 4).
2. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/ SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. JАCC 2012; 60 (24): e44-e164. doi: 10.1016/j. jacc.2012.07.013.
3. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34 (38):2949–3003.
4. Oganov RG, Lepakhin VK, Fitilev SB, et al. Diagnosis and therapy of stable angina in Russian Federation (International Study ATP — angina treatment pattern). Kardiologiia. 2003; 43 (5):9–15. Russian (Оганов Р.Г., Лепахин В.К., Фитилев С.Б. и др. Особенности диагностики и терапии стабильной стенокардии в Российской Федерации (международное исследование ATP — Angina Treatment Pattern). Кардиология 2003; № 5: 9–15).
5. Bubnova MG, Aronov DM, Oganov RG, et al. (on behalf of the study investigators) Clinical characteristics of stable angina patients and their treatment strategies in real-world clinical practice. A Russian PERSPECTIVE Study (Part I). Cardiovascular Therapy and Prevention 2010; 6:47–56. Russian (Бубнова М. Г., Аронов Д. М., Оганов Р. Г. от имени исследователей. Клиническая характеристика и общие подходы к лечению пациентов со стабильной стенокардией в реальной клинической практике. Российское исследование ПЕРСПЕКТИВА (ч. I). Кардиоваскулярная терапия и профилактика 2010; 6:47–56).
6. Glezer MG, Saĭgitov RT.Adherence of patients with stable angina to treatment with trimetazidine MR and frequency of emergency medical care: results of the EFFECT study Kardiologiia 2012; 52 (11):4–11. Russian (Глезер М. Г., Сайгитов Р. Т. Приверженность больных со стабильной стенокардией к лечению триметазидином МВ и ее связь с частотой обращений за медицинской помощью по экстренным показаниям: результаты исследования ЭФФЕКТ. Кардиология. 2012; 52 (11):4–11).
7. Tardif JC, Ford I, Tendera M, et al. INITIATIVE Investigators. Efficacy of ivabradine, a new selective I (f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005; 26 (23):2529–36.
8. Ruzyllo W, Tendera M, Ford I, Fox KM. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs 2007; 67 (3):393–405.
9. Steg PG, Ferrari R, Ford I, et al. CLARIFY Investigators. Heart rate and use of beta-blockers in stable outpatients with coronary artery disease. PLoS One. 2012; 7 (5): e36284. doi: 10.1371/journal.pone.0036284.
10. Heidenreich PA, McDonald KM, Hastie T, et al. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA 1999; 281 (20):1927–36.
11. Tardif JC, Ponikowski P, Kahan T; ASSOCIATE Study Investigators.Efficacy of the I (f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 2009; 30 (5):540–8.
12. Glezer MG, Saĭgitov RT. Antianginal efficacy and tolerability of ivabradine in the therapy of patients with stable angina: results of the CONTROL study. Kardiologiia 2010; 50 (11):65–75. Russian (Глезер М. Г., Сайгитов Р.Т. Антиангинальная эффективность и переносимость ивабрадина в терапии пациентов со стабильной стенокардией: результаты исследования КОНТРОЛЬ. Кардиология 2010; (11): 65–75).
13. Glezer MG. LINKOR: results of observational program in patients with myocardial infarction. Kardiologiia 2013; 53 (5):74–82. Russian (Глезер М. Г. от лица участников программы. ЛИНКОР: результаты наблюдательной программы лечения пациентов, перенесших инфаркт миокарда. Кардиология 2013; 5:109–17).
14. Werdan K, Ebelt H, Nuding S, et al. Ivabradine in combination with betablocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study. Clin Res Cardiol 2012; 101 (5):365–73.
15. Glezer MG, Astashkin EI. Pharmacological correction of heart rate in myocardial ischemia. Ter archive 2012; 4:68–73. Russian (Глезер М.Г., Асташкин Е.И. Фармакологическая коррекция частоты сердечных сокращений при ишемии миокарда. Тер архив 2012; 4:68–73).
16. Karpov YuA, Glezer MG, Vasyuk YuA, et al. Antianginal effectiveness and tolerability of ivabradine in patients with stable angina: CONTROL-2 Study results. Cardiovascular Therapy and Prevention 2011; 10 (8):83–9. Russian (Карпов Ю. А., Глезер М. Г., Васюк Ю. А. и др. Антиангинальная эффективность и переносимость ивабрадина в терапии пациентов со стабильной стенокардией: результаты исследования КОНТРОЛЬ-2. Кардиоваскулярная терапия и профилактика 2011; 10 (8):83–9).
17. Fox K, Ford I, Steg PG, et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomized controlled trial. Lancet 2008; 372 (9641): 817–21.
18. Swedberg K, Komajda M, Böhm M. et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376 (9744):875–85.
19. Böhm M, Swedberg K, Komajda M, et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010; 376 (9744):886–94.
20. Swedberg K, Komajda M, Böhm M, et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I (f) inhibitorivabradine Trial) study. JACC 2012; 59 (22):1938–45.
21. Tardif JC, O’Meara E, Komajda M, et al. SHIFT Investigators. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J 2011; 32 (20):2507–15.
Review
For citations:
Glezer M.G., Astashkin E.I., Sokolova I.N. ROLE OF MEDICATIONS WITH NEGATIVE CHRONOTROPIC EFFECT IN THE TREATMENT OF PATIENTS WITH CORONARY HEART DISEASE AND HEART FAILURE. Cardiovascular Therapy and Prevention. 2013;12(5):81-86. (In Russ.) https://doi.org/10.15829/1728-8800-2013-5-81-86
Views:
1744
Email this article 
